๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

28 recruiting trials

for Low Risk Myelodysplastic Syndromes

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts NCT05365035Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cladribine, Cytarabine, Venetoclax, Azacitidine Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome NCT01624805Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone, Pegfilgrastim Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation NCT07753148Phase 12 sites๐Ÿ“ Ghent๐Ÿ“ Roeselare Regeneron Pharmaceuticals ยท Tests: REGN17235 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome NCT02269592n/a7 sites๐Ÿ“ Boston๐Ÿ“ Brighton๐Ÿ“ Methuen Dana-Farber Cancer Institute A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) NCT03886662Phase 1, Phase 21 site๐Ÿ“ Tampa Lixte Biotechnology Holdings, Inc. ยท Tests: LB-100 A Study to Evaluate the MNV-201 in Patients With Low Risk MDS NCT06465160Phase 11 site๐Ÿ“ Jerusalem Minovia Therapeutics Ltd. ยท Tests: MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria) A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions NCT06499285Phase 3182 sites๐Ÿ“ Duarte๐Ÿ“ Glendale๐Ÿ“ La Jolla Takeda ยท Tests: Elritercept, Placebo A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes NCT07319845Phase 221 sites๐Ÿ“ Tokyo๐Ÿ“ Fukui๐Ÿ“ Hiroshima Takeda ยท Tests: TAK-226 Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) NCT06670222Phase 13 sites๐Ÿ“ Nice๐Ÿ“ Paris๐Ÿ“ Villejuif Groupe Francophone des Myelodysplasies ยท Tests: Arsenic Trioxide (ATO) Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187Phase 21 site๐Ÿ“ Hong Kong The University of Hong Kong ยท Tests: Oral arsenic trioxide A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions NCT07422480Phase 3162 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Santa Rosa Takeda ยท Tests: Elritercept, Epoetin Alfa A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome NCT06847867Phase 239 sites๐Ÿ“ Goodyear๐Ÿ“ Duarte๐Ÿ“ Irvine GlaxoSmithKline ยท Tests: Momelotinib Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML NCT05184842Phase 23 sites๐Ÿ“ Sacramento๐Ÿ“ The Bronx๐Ÿ“ White Plains Montefiore Medical Center ยท Tests: Venetoclax, Decitabine FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia NCT07283094Phase 11 site๐Ÿ“ The Bronx Montefiore Medical Center ยท Tests: Decitabine, Venetoclax, FHD-286 Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples NCT04251078n/a1 site๐Ÿ“ Badalona Josep Carreras Leukaemia Research Institute A Trial Testing SP-420 in Subjects With Transfusion-dependent ฮฒ-thalassemia or Low-risk Myelodysplastic Syndromes NCT05693909Phase 21 site๐Ÿ“ Copenhagen Pharmacosmos A/S ยท Tests: SP-420 Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions NCT06773871NA2 sites๐Ÿ“ Copenhagen๐Ÿ“ Copenhagen Copenhagen University Hospital, Rigshospitalet ยท Tests: Exercise, Control A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1ฮฒ Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia NCT04239157Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Canakinumab Pre-myeloid Cancer and Bone Marrow Failure Clinic Study NCT02958462NA3 sites๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Punch Biopsy, Buccal Swab, Clinical Evaluation A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) NCT04419649Phase 253 sites๐Ÿ“ Hot Springs๐Ÿ“ Duarte๐Ÿ“ Miami Takeda ยท Tests: Elritercept Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) NCT05308264Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Orange๐Ÿ“ Palo Alto Rigel Pharmaceuticals ยท Tests: R906289 Monosodium (R289 Na) Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) NCT01515527Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cladribine, Cytarabine, Decitabine Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions NCT05384691Phase 222 sites๐Ÿ“ Berlin๐Ÿ“ Bonn๐Ÿ“ Cottbus University of Leipzig ยท Tests: Luspatercept Injection Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation NCT07249346Phase 23 sites๐Ÿ“ Birmingham๐Ÿ“ Boston๐Ÿ“ Columbus Hannah Choe, MD ยท Tests: Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus Combining Active and Passive DNA Hypomethylation NCT03999723Phase 210 sites๐Ÿ“ Aalborg๐Ÿ“ Aarhus๐Ÿ“ Copenhagen Kirsten Grรธnbรฆk ยท Tests: Vitamin C, Placebo Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms NCT06063486Phase 22 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles University of Southern California ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-coโ€ฆ Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients NCT07763054n/a1 site๐Ÿ“ Hainan Haikou Affiliated Hospital of Central South University Xianโ€ฆ ยท Tests: Liposomal Amphotericin B Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS NCT05636514Phase 15 sites๐Ÿ“ Sydney๐Ÿ“ Sydney๐Ÿ“ Sydney Clinical Hub for Interventional Research (CHOIR) ยท Tests: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Defactinib
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy